EN DE
Watch LB Pharmaceuticals Inc Common Stock for free: we tell you when fair value or trend changes.
Data-driven stock valuation

LB Pharmaceuticals Inc (LBRX) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of LB Pharmaceuticals Inc stock $7.82, price $42.01, that is 81.4% below the price, quality 43 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

LP LB Pharmaceuticals Inc logo Thin data Nov 6, 2026

LB Pharmaceuticals Inc

LBRX · US
Very expensive, weak quality

Our calculation puts a fair price 81% below what the stock costs today.

Quality 43/100
Fair value $7.82 · Strongly overvalued
Negative free cash flow
Trails peers (3/8)
Narrow moat 12/100 · thin data
Thin data
⚠ Dilution
Watch LB Pharmaceuticals Inc Common Stock for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$49.48 $14.61 Fair Value $7.82 Sep 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

14‑month range $14.61 – $49.48 · fair‑value band $5.16 – $9.78 · the $42.01 price screens above the $7.82 fair value. As of Nov 6, 2026.

Follow LB Pharmaceuticals Inc Common Stock in your weekly email

Every Wednesday you see whether LB Pharmaceuticals Inc Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.

Show moreShow less

Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.

The company was incorporated in 2015 and is headquartered in New York, New York.

Stock analysis

LB Pharmaceuticals Inc (LBRX) currently trades at $42.01, while our model-based Fair Value estimate is $7.82, 81% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 92/100, which puts the data coverage at low.

Scenario range: $5.16 (bear) to $9.78 (bull), the price of $42.01 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

LB Pharmaceuticals Inc Common Stock reported revenue of $0 in FY2025 versus $0 in FY2022. Reported net income was −$25.2M in FY2025.

Key figures

Market cap $1.3B Small · P/E ratio 420.1 · EPS (TTM) $0.1000 · Return on equity −50.0% · Return on assets (EBIT) −60.3% (4-year average) · Free cash flow −$35.3M · Net cash $247M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

Analysts expect earnings well below the last reported figure (earnings in transition, for example expiring patents or contracts); a fair value that looks fair on trailing earnings may then be too optimistic.

The share trades about 15% below its 52-week high and 188% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −81%, LBRX screens richer than that median.

Fair Value models

Bear $5.16 Fair Value $7.82 Bull $9.78
Price $42.01 · Downside -81.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.0858 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $6.07 $9.20 $11.50 52
All 1 models by family
Asset-Based
NCAV (Graham) $6.07 $9.20 $11.50 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 43/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 60
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 72
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 89
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

LBRX screens overvalued: fair value 81% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare LB Pharmaceuticals Inc Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 43 · Below median
Fair Value upside −81.4% · Bottom 25%
Profitability
Return on assets −8.1% · Above median
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 420.1× · Priciest 25%
P/B 4.20× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs LBRX
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs LBRX
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs LBRX
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs LBRX
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs LBRX
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs LBRX
argenx SE ARGX $927.21 $908.40 −2% vs LBRX
CSL Limited CSL A$200.77 A$183.04 −9% vs LBRX
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs LBRX
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs LBRX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

LB Pharmaceuticals Inc Common Stock: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "LB Pharmaceuticals Inc Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/LBRX

Frequently asked questions

Is LB Pharmaceuticals Inc (LBRX) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $7.82 versus a price of $42.01, about 81% lower (overvalued).
What is the fair value of LBRX?
Our model-based fair value for LB Pharmaceuticals Inc is $7.82 (as of Nov 6, 2026), built from audited fundamentals. The current price: $42.01.
What is the quality score of LBRX?
LB Pharmaceuticals Inc has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for LB Pharmaceuticals Inc (LBRX)?
Our model-based price target is the fair value of $7.82 (as of Nov 6, 2026) from 1 valuation models. Cautious scenario $5.16, optimistic scenario $9.78. It is a calculation from audited fundamentals, not an analyst target.
What is the LB Pharmaceuticals Inc Common Stock stock forecast for 2026?
Our models put fair value at $7.82, about 81% lower versus a price of $42.01 (overvalued). Cautious scenario $5.16, optimistic scenario $9.78. The calculation is refreshed regularly with new filings.
What is the intrinsic value of LB Pharmaceuticals Inc (LBRX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For LB Pharmaceuticals Inc it is $7.82 per share (as of Nov 6, 2026), against a price of $42.01. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is LB Pharmaceuticals Inc Common Stock stock overvalued or undervalued in 2026?
As of Nov 6, 2026, LBRX trades above its calculated fair value: price $42.01, fair value $7.82, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LBRX?
No. The price is what the market pays today ($42.01); the fair value is what the company's own numbers justify ($7.82). For LB Pharmaceuticals Inc the two are $34.19 per share apart. That gap is exactly why we show both numbers side by side.
How much is LB Pharmaceuticals Inc Common Stock worth?
The market values LB Pharmaceuticals Inc at about $1.3B (market capitalisation, as of Nov 6, 2026). Per share that is $42.01; our models calculate a fair value of $7.82 per share.
What do the bullish and bearish scenarios say about LBRX?
Our models span a range for LB Pharmaceuticals Inc: cautious scenario $5.16, base $7.82, optimistic $9.78 per share (as of Nov 6, 2026, price $42.01). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of LBRX?
LB Pharmaceuticals Inc trades at a price-to-earnings ratio of 420.1 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $7.82 is built from several models across several years. Other multiples: P/B 4.2.
How solid is the balance sheet of LB Pharmaceuticals Inc (LBRX)?
Balance-sheet figures for LB Pharmaceuticals Inc (as of Nov 6, 2026): return on equity −50.0%. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is LBRX from its 52-week high?
LB Pharmaceuticals Inc trades at $42.01, about 15% below its 52-week high of $49.48 and 188% above the low of $14.61 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $7.82 is for.
Which stocks are comparable to LB Pharmaceuticals Inc Common Stock?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is LB Pharmaceuticals Inc Common Stock stock attractive at the current price?
The data as of Nov 6, 2026: price $42.01, calculated fair value $7.82 (−81%), Quality Score 43/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LBRX calculated?
We run LB Pharmaceuticals Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $7.82 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. LB Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of LB Pharmaceuticals Inc (LBRX)?
The closing price on Nov 6, 2026 was $42.01. Our model-based fair value is $7.82, about 81% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with LB Pharmaceuticals Inc Common Stock right now?
The price sits above even our optimistic bull case ($9.78). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($5.16 to $9.78) leaves room in how you read the outcome.

Key figures of LB Pharmaceuticals Inc

How large is the market capitalisation of LB Pharmaceuticals Inc (LBRX)?
The market capitalisation of LB Pharmaceuticals Inc is $1.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of LB Pharmaceuticals Inc (LBRX)?
Earnings per share at LB Pharmaceuticals Inc are $0.1000 (price ÷ EPS = P/E 420.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of LB Pharmaceuticals Inc (LBRX)?
The return on equity (ROE) of LB Pharmaceuticals Inc is −50.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of LB Pharmaceuticals Inc (LBRX)?
On an EBIT basis the return on assets of LB Pharmaceuticals Inc is −60.3% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does LB Pharmaceuticals Inc (LBRX) generate?
The free cash flow of LB Pharmaceuticals Inc is −$35.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does LB Pharmaceuticals Inc (LBRX) hold?
LB Pharmaceuticals Inc holds more cash than debt, $247M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch LB Pharmaceuticals Inc Common Stock in the live analysis

One click puts LB Pharmaceuticals Inc Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.